ADVM
Closed
Adverum Biotechnologies Inc
2.28
+0.13 (+6.05%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.15
Day's Range: 2.11 - 2.365
Send
sign up or login to leave a comment!
When Written:
0.722
Adverum Biotechnologies Inc. is a clinical-stage gene therapy company that is focused on developing treatments for ocular and rare diseases. The company was founded in 2006 and is headquartered in Redwood City, California. Adverum's lead product candidate is ADVM-022, a gene therapy for the treatment of wet age-related macular degeneration (AMD). The company is also developing gene therapies for the treatment of rare diseases such as alpha-1 antitrypsin deficiency and hereditary angioedema. Adverum has partnerships with Regeneron Pharmaceuticals and Editas Medicine to develop gene therapies for ocular diseases. The company went public in 2014 and is traded on the NASDAQ under the ticker symbol ADVM.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








